{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:51:42Z","timestamp":1786978302463,"version":"build-2736575974"},"reference-count":84,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aims to analyze the health\u2010related quality of life (HRQoL) and safety outcomes in attention\u2010deficit\/hyperactivity disorder (ADHD) patients treated with cannabis\u2010based medicinal products (CBMPs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in the following patient\u2010reported outcome measures (PROMs) at 1, 3, 6, and 12\u2009months from baseline: EQ\u20105D\u20105L index value, generalized anxiety disorder\u20107 (GAD\u20107) questionnaire, and the single\u2010item sleep quality score (SQS). Secondary outcomes assessed the incidence of adverse events. Statistical significance was defined as\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.050.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty\u2010eight patients met the inclusion criteria. Significant improvements were identified in general HRQoL assessed by EQ\u20105D\u20105L index value at 1, 3, and 6\u2009months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.050). Improvements were also identified in GAD\u20107 and SQS scores at 1, 3, 6, and 12\u2009months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.010). 61 (89.71%) adverse events were recorded by 11 (16.18%) participants, of which most were moderate (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926, 38.24%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An association between CBMP treatment and improvements in anxiety, sleep quality, and general HRQoL was observed in patients with ADHD. Treatment was well tolerated at 12\u2009months. Results must be interpreted with caution as a causative effect cannot be proven. These results, however, do provide additional support for future evaluation within randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/npr2.12400","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T18:35:04Z","timestamp":1701974104000},"page":"596-606","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["UK Medical Cannabis Registry: An analysis of clinical outcomes of medicinal cannabis therapy for attention\u2010deficit\/hyperactivity disorder"],"prefix":"10.1002","volume":"43","author":[{"given":"Pim","family":"Ittiphakorn","sequence":"first","affiliation":[{"name":"Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-6501","authenticated-orcid":false,"given":"Simon","family":"Erridge","sequence":"additional","affiliation":[{"name":"Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"},{"name":"Sapphire Medical Clinics  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Holvey","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Coomber","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics  London UK"},{"name":"St. George's Hospital NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Rucker","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine Kings College London  London UK"},{"name":"South London &amp; Maudsley NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael H.","family":"Sodergren","sequence":"additional","affiliation":[{"name":"Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"},{"name":"Sapphire Medical Clinics  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.09.2206"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.11.04009"},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","unstructured":"Visser SN Danielson ML Bitsko RH Holbrook JR Kogan MD Ghandour RM et al. Trends in the Parent\u2010Report of Health Care Provider\u2010Diagnosis and Medication Treatment for ADHD disorder: United States 2003\u20132011. J Am Acad Child Adolesc Psychiatry. 2014 53(1):34\u201346.e2.","DOI":"10.1016\/j.jaac.2013.09.001"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.14344"},{"issue":"5","key":"e_1_2_11_6_1","first-page":"467","article-title":"ADHD diagnostic trends: increased recognition or overdiagnosis?","volume":"119","author":"Abdelnour E","year":"2022","journal-title":"Mo Med"},{"key":"e_1_2_11_7_1","unstructured":"DSM\u20105 changes: Implications for child serious emotional disturbance.2016[cited 2023 Feb 7]. Available from:https:\/\/pubmed.ncbi.nlm.nih.gov\/30199184\/"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.20"},{"key":"e_1_2_11_9_1","unstructured":"World Health Organization.ICD\u201011: International Classification of Diseases 11th Revision.2018. Available from:https:\/\/icd.who.int\/. Accessed January 2021."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2016.01230"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12402\u2010014\u20100142\u20101"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551\u20106776\u201021.3.192"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.02.001"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.21037\/tp.2017.08.02"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2019.04.009"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/10870547211050949"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787\u2010016\u20100919\u20101"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.01.2112"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2011.00057"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755\u20105949.2010.00144.x"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2012.01.008"},{"key":"e_1_2_11_22_1","volume-title":"The endocannabinoid system: essential and mysterious [Internet]","author":"Grinspoon P","year":"2021"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030833"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2016.00294"},{"key":"e_1_2_11_25_1","unstructured":"DawsonDA PersadCP.Targeting the endocannabinoid system in the treatment of ADHD [Internet]. Scivisionpub.com. [cited 2023 Feb 7]. Available from:https:\/\/scivisionpub.com\/pdfs\/targeting\u2010the\u2010endocannabinoid\u2010system\u2010in\u2010the\u2010treatment\u2010of\u2010adhd\u20101604.pdf"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207693"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.30693"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2011.07876.x"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00004.2003"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.54.2.161"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702\u2010021\u201002326\u2010y"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2006.03880.x"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312457586"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2012.04341.x"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13250"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311\u2010015\u20100377\u20103"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986607780090829"},{"key":"e_1_2_11_38_1","volume-title":"Cannabis\u2010based medicinal products","year":"2021"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/medlaw\/fwaa002"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.05.005"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2022.11.029"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2013.08.003"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10802\u2010015\u20100012\u20100"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888\u2010021\u201003263\u20106"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2019.1626030"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.596601"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380\u2010018\u20100339\u20103"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2011.01.006"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.01.032"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1998.10399692"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e31829f9119"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054716640109"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12183"},{"key":"e_1_2_11_54_1","first-page":"1453","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","author":"Von Elm E","journal-title":"Bull World Health Organ"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1089\/can.2016.0025"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021\u20109681(87)90171\u20108"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.5664\/JCSM.7478"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/S11136\u2010011\u20109903\u2010X"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JPAIN.2009.01.258"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.01.032"},{"key":"e_1_2_11_62_1","unstructured":"Position statement on use of the EQ\u20105D\u20105L value set for England (updated October 2019)|Technology appraisal guidance|NICE guidance|Our programmes|What we do|About|NICE. [cited 2023 May 2]. Available from:https:\/\/www.nice.org.uk\/about\/what\u2010we\u2010do\/our\u2010programmes\/nice\u2010guidance\/technology\u2010appraisal\u2010guidance\/eq\u20105d\u20105l"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.s8135"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774515602688"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAONCOL.2015.2639"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.0109"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1159\/000521370"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181d236ec"},{"key":"e_1_2_11_69_1","unstructured":"Strohbeck\u2010KuehnerP SkoppG MatternR.Cannabis improves symptoms of ADHD [Internet].2008. Free.fr [cited 2023 Feb 7]. Available from:http:\/\/mcforadhd.free.fr\/ARTICLE%20ADHD%20DRIVING%20GERMANY.pdf"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1177\/20451253221116240"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2022.2155139"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2022.2161894"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213\u2010023\u201006399\u20103"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.2147\/NSS.S163074"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2020.00125"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311\u2010021\u201001013\u2010w"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2019-001938"},{"key":"e_1_2_11_78_1","unstructured":"VlessidesM.Cannabis for sleep: short\u2010term benefit long\u2010term disruption? [Internet].2020. Mdedge.com. Frontline Medical Communications Inc. [cited 2023 May 2]. Available from:https:\/\/www.mdedge.com\/chestphysician\/article\/216153\/sleep\u2010medicine\/cannabis\u2010sleep\u2010short\u2010term\u2010benefit\u2010long\u2010term\u2010disruption"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.2147\/NSS.S31269"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2020640"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2009.05.004"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244012"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u2010244X\u201013\u2010298"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240810"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.07.014"}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T02:26:09Z","timestamp":1704507969000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.12400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/npr2.12400"],"URL":"https:\/\/doi.org\/10.1002\/npr2.12400","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"2023-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}